



07-07-06 IAP6 Rec'd PCT/PTO 06 JUL 2006

CASE 33568-US-PCT

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV7272742R5US  
Express Mail Label Number

July 6, 2006  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
ISABEL OTTINGER  
INTERNATIONAL APPLICATION NO: PCT/EP3004/014433  
FILED: 17 DECEMBER 2004  
U.S. APPLICATION NO: 10/580,258  
35 USC §371 DATE: 24 MAY 2006  
FOR: MICROEMULSION PRECONCENTRATE COMPRISING A RENIN  
INHIBITOR

**MS: Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



---

Gregory D. Ferraro  
Attorney for Applicant  
Reg. No. 36,134

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7831

Date:

6/30/06

ATTY. DOCKET NO.  
33568-US-PCT  
APPLICATION NO.  
10/580,258  
APPLICANT  
Isabel Ottinger  
FILING DATE  
MAY 24, 2006

Group

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
*	AA	2001/0007663	7/12/01	Corswant	424	400	
	AB	2002/0120015	8/29/02	Dennis et al.	514	772.3	
	AC	2002/0077372	6/20/02	Gers-Barlag et al.	516	98	
	AD	2004/0052824	3/18/04	Abou Chacra-Vernet et al.	424	400	
	AE	4,719,239	1/12/88	Muller et al.	514	785	
	AF	5,559,111	9/24/96	Goeschke et al.	514	227.5	
	AG	5,633,226	5/27/97	Owen et al.	514/2	424/400	
	AH	5,646,109	7/8/97	Owen et al.	514/2	424/400	
	AI	5,688,761	11/18/97	Owen et al.	514/2	424/400	
	AJ	5,897,876	4/27/99	Rudnic et al.	424	455	
	AK	5,952,004	9/14/99	Rudnic et al.	424	455	
	AL	5,993,858	11/30/99	Crison et al.	424	490	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	EP 0 214 501	9/23/92	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	EP 0 448 091	9/25/91	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AO	EP 0 591 452	4/13/94	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AP	EP 0597 007	5/18/94	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	EP 0597 029	5/18/94	EP			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

*	AR	Database WPI, Section Ch, Week 199749, AN 1997-201987 (18), XP-002323586 & ZA 9 700 457 A (ASTRA AB) (1997)
	AS	Kararli et al., Pharmaceutical Research, Vol. 9, No. 7, pp. 888-893, "Oral Delivery of a Renin Inhibitor Compound Using Emulsion Formulations. (1992).
	AT	Stanton, Journal of the Renin-Angiotensin-Aldosterone System, Vol. 4, No. 1, pp. 6-10, "Potential of renin inhibition in cardiovascular disease" (2003).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

***(Use several sheets if necessary)***

**ATTY. DOCKET NO.**  
33568-US-PCT  
**APPLICATION NO.**  
10/580,258  
**APPLICANT**  
Isabel Ottinger  
**FILING DATE**  
MAY 24, 2006

**Group**

## U.S. PATENT DOCUMENTS

[illegible]

**EXAMINER**

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
33568-US-PCT  
APPLICATION NO.  
10/580,258  
APPLICANT  
Isabel Ottinger  
FILING DATE  
MAY 24, 2006

Group

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CA	EP 0753 311	1/15/97	EP			<input type="checkbox"/>	<input type="checkbox"/>
	CB	EP 1 170 003	1/9/02	EP			<input type="checkbox"/>	<input type="checkbox"/>
*	CC	EP 1 312 379	5/21/03	EP			<input type="checkbox"/>	<input type="checkbox"/>
*	CD	GB 2 222 770	3/21/90	GB			<input type="checkbox"/>	<input type="checkbox"/>
	CE	WO 02/09764	2/7/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CF	WO 00/33862	6/15/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CG	WO 00/67888	11/16/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CH	WO 01/28555	4/26/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CI	WO 01/68139	9/20/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CJ	WO 02/064166	8/23/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CK	WO 02/09671	2/7/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CL	WO 02/09764	2/7/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CM	WO 03/068186	8/21/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CN	WO 90/08537	8/9/90	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CO	WO 93/02664	2/18/93	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CP	WO 94/08603	4/28/94	WO			<input type="checkbox"/>	<input type="checkbox"/>
*	CQ	WO 94/08605	4/28/94	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CR	WO 94/08610	4/28/94	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CS	WO 95/14037	5/26/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CT	WO 95/24893	9/21/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CU	WO 95/25504	9/28/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CV	WO 95/28920	11/2/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CW	WO 98/00169	1/8/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CX	WO 98/51280	11/19/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CY	WO 99/43299	9/2/99	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CZ	WO 99/44732	9/10/99	WO			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
33568-US-PCT  
APPLICATION NO.  
10/580,258  
APPLICANT  
Isabel Ottinger  
FILING DATE  
MAY 24, 2006

Group

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BN	Derwent Abstract, Dahms et al., WO 9218227, 10/29/1992, „Stable multiple emulsions for cosmetic use, etc. – contains a mixt. Of emulsifiers with low and high HLB values, WPI 1992-350728.
BO	Derwent Abstract, Supersaxo et al., WO 200128520, 04/26/2001, "Microemulsion preconcentrate containing triglyceride, fatty acid and surfactant, spontaneously forming emulsion in water, useful as carrier for water-insoluble active agents, e.g. drugs. WPI 2001-397572.
BP	Derwent Abstract, Morinaga Milk Co., JP 61185332, 08/19/1986, "Stable emulsion for dispersing water in oil – contains high m.pt. lipid(s), emulsifier e.g. fatty acid ester of sorbitan and water" WPI 1986-255932
BQ	Derwent Abstract, Shiseido Co LTD, JP 63126543, 05/30/1988, "Microemulsion for use in medical and cosmetic compns. – comprises more than 2 oils, water and hydrophilic nonionic surfactant, WPI 1988-187881.
BR	Derwent Abstract, Inada et al., WO0059470, 7/16/00, "Oil-in-water emulsions comprise surfactant to increase solubility of drug in oil" WPI 2000-656199/200063
BS	Derwent Abstract, SANKYO CO LTD, JP 4164024, 6/9/92, Prepn. of self-emulsion type fatty compsn. contg. medicine – by dilution of mixt. of e.g. vegetable oil, nonionic surfactant, solvent and medicated cpd. (WPI 1992-239894/199229.
BT	Derwent Abstract, NIPPON OILS, JP 61135572, 06/23/1986, "Lipid emulsion – comprises oil contg. tri-saturated glyceride and palmitic acid, water and emulsifier, .
BU	Derwent Abstract, Advanced Skin Res Kenkyusho KK, JP 11009988, 01/19/1999, "Water-in-oil type microemulsion – comprising oil, surfactant and water, WPI 1999-146517.
BV	Derwent Abstract, Nikko Chem. KK, , JP 093855, 12/24/91, "Stable oil-water emulsion comprises all soluble surfactant as emulsifier, with all phase dispersed in aq. phase
BW	Derwent Abstract, Shiseido KK, JP 274531, 5/30/88, "Micro emulsion, esp. useful for medical or cosmetic fields – contg. hydrophilic nonionic surfactant, specified oil(s) and water.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.